CarboCell is an injectable material designed to release antibiotics directly where bone infections occur. We tested it in animals and found that it delivered high and long-lasting drug levels in bone while keeping drug levels in the rest of the body very low. This suggests that CarboCell may improve infection treatment and reduce the need for whole-body antibiotic therapy.

This study examined how people with difficult joint infections manage long-term antibiotic treatment when the infection cannot be fully removed. We followed patients to record side effects and overall well-being. Many had stomach or skin problems, but most continued treatment. The results show that attentive follow-up and personalised care keep this therapy manageable and may guide better support in practice.